The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.
Patients with B-cell-ALL (≤ 25 years) or patients with DLBCL (18-70 years) or patients with PMBCL (18-70 years) who were relapsed/refractory after two lines of treatments;
Adequate performance status (0 or 1);
Adequate organ function;
No active or uncontrolled infections;
Patients with B-cell-ALL > 25 years
Patients with DLBCL <18 or >70 years
Patients with PMBCL <18 or >70 years
Performance status > 1;